Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

HPAI vaccine trials begin in the UK
Turkeys have been selected dur to their high susceptibility to HPAI.
Trials will focus on turkeys in England.

The Department for Environment, Food and Rural Affairs (Defra) has today (5 March) launched a targeted vaccine trial on turkeys in England.

The new trials will explore how these vaccines could be used as an additional tool to control highly pathogenic avian influenza (HPAI).

Researchers will study whether these vaccines can be used to protect birds, with a specific focus on turkeys in England. The trial is expected to provide insight into how these vaccines work in the field and manage the disease, contributing to a growing international body of HPAI vaccination research.

The project will also examine the use of surveillance to retain the trade of turkeys.

Researchers have selected turkeys as the priority species for this study due to their high susceptibility to avian influenza. Outbreaks among turkeys will result in severe clinical signs, including rapid mortality rates.

With approval from the Veterinary Medicines Directorate (VMD), the trial will sample a small group of birds under strict supervision using UK/EU authorised vaccines. The trial will last for 24 weeks.

Defra reports an ‘unprecedented’ amount of avian influenza outbreaks in both the UK and in Europe over the past few years. The diseases has impacted both captive and wild birds globally since 2020, which Defra says has caused ‘devastation’ to birdkeepers on the frontline and in the poultry sector.

Christine Middlemiss, chief veterinary officer, said: “This targeted trial is going to be really key for our understanding of how HPAI vaccines can be effectively used for disease control in the UK. They have the potential to be a really valuable additional tool in helping us protect birds from infection.  
 
“Stringent biosecurity will always remain our best defence and [we] urge all bird keepers to continue to take the steps needed to prevent avian influenza spreading onto their premises.”

Baroness Hayman, biosecurity minister, said: “The start of new vaccine trials are a significant step forward in our fight against this disease and will contribute to global research efforts. We are hopeful vaccines can be used in the UK as an additional tool to control bird flu to protect the UK's biosecurity and food supply.”

Image © Shutterstock.com/Sergey kolesnikov

Become a member or log in to add this story to your CPD history

Vets launch new podcast for pet owners

News Story 1
 Two independent vets have launched a podcast to help owners strengthen their bond with pets. Dr Maggie Roberts and Dr Vanessa Howie, who have worked in both veterinary practice and major charities, are keen to use their experience to enable people to give pets a better life.

The venture, called Vets Talking Pets, provides advice and information on a range of topics, including how to select a suitable pet, where to obtain them and how to get the best out of your vet. Maggie and Vanessa will also discuss sensitive subjects, including end-of-life care, raw food diets and the cost of veterinary care.

The podcast can be found on all the usual podcast sites, including Podbean, Apple, Amazon Music and YouTube. 

Click here for more...
News Shorts
VMD issues guidance on AVM-GSL packaging

The Veterinary Medicines Directorate (VMD) has shared advice on its requirements for medicines considered AVM-GSL.

The guidance explains the information that should be on the outer package, and sets out the typical maximum pack size for an AVM-GSL product. It also describes the user-friendly language, structure and phrases required on packaging and product leaflets.

AVM-GSL products do not require discussion between the purchaser and a veterinary professional. This means that clear product information is needed to support sales choices.

The information will be useful for submitting new products to the AVM-GSL category and lowering the distribution category of products from NFA-VPS to AVM-GSL.

The VMD's guidance can be accessed here.